ProfileGDS5678 / 1426980_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 41% 41% 41% 41% 40% 39% 40% 40% 41% 41% 41% 40% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0701444
GSM967853U87-EV human glioblastoma xenograft - Control 22.938641
GSM967854U87-EV human glioblastoma xenograft - Control 32.9426941
GSM967855U87-EV human glioblastoma xenograft - Control 42.8862441
GSM967856U87-EV human glioblastoma xenograft - Control 52.889441
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0014540
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9624739
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9185440
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8912140
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9294641
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9265241
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9108341
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9353640
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9316841